ストックスクリーナーアプリを入手
1.60
7.02%
-0.11
Dogwood Therapeutics Inc (DWTX) 最新ニュース
Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest - MarketBeat
Dogwood Therapeutics receives FDA clearance for SP16 pain trial By Investing.com - Investing.com South Africa
Dogwood Therapeutics Announces FDA Acceptance of SP16 - GlobeNewswire
Decliners Report: How volatile is Dogwood Therapeutics Inc stock2026 Market WrapUp & AI Driven Stock Movement Reports - baoquankhu1.vn
Will Dogwood Therapeutics Inc benefit from government policyCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn
Investment Report: Will Dogwood Therapeutics Inc benefit from geopolitical trends2026 Institutional & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-04-11 05:48:42 - baoquankhu1.vn
Activity Recap: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Performance Recap: How sensitive is Dogwood Therapeutics Inc to inflationEarnings Summary Report & Proven Capital Preservation Methods - baoquankhu1.vn
Aug Weekly: Should I invest in Dogwood Therapeutics Inc before earnings2026 Key Lessons & Risk Controlled Swing Alerts - baoquankhu1.vn
Downgrade Watch: How sensitive is Dogwood Therapeutics Inc to inflationMarket Sentiment Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Sentiment Watch: What is the PEG ratio of Dogwood Therapeutics IncCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Dogwood Therapeutics Reports Q1 2026 Progress: Advances in Halneuron® and SP16 for Cancer-Related Pain and Neuropathy, $12.5M Raised - Minichart
Analysts Issue Forecasts for DWTX Q1 Earnings - Defense World
Dogwood Therapeutics Highlights Pipeline Progress and Extended Runway - TipRanks
Dogwood Therapeutics (NASDAQ: DWTX) details non-opioid pain pipeline in Q1 2026 update - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Q1 Earnings Estimate for DWTX Issued By Zacks Research - MarketBeat
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - MarketBeat
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) ramps R&D and extends cash runway - Stock Titan
Dogwood Therapeutics Q4 net loss narrows on lower expenses - TradingView
Dogwood Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1% - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7%Time to Buy? - MarketBeat
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal - The Globe and Mail
Dogwood Therapeutics, Inc. 8-K SEC Filing March 11, 2026: Company Information, Stock, and Key Details - Minichart
Dogwood Therapeutics (Nasdaq: DWTX) holders back major warrant exercise - Stock Titan
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development - The Manila Times
Sentiment Watch: What is the long term forecast for Dogwood Therapeutics Inc stockTrend Reversal & Accurate Buy Signal Alerts - baoquankhu1.vn
Maxim Group Sticks to Its Buy Rating for Dogwood Therapeutics (DWTX) - The Globe and Mail
Dogwood Therapeutics (DWTX) CMO receives grant of 82,500 stock options - Stock Titan
Dogwood Therapeutics (DWTX) SVP awarded 82,500-share stock option grant - Stock Titan
DWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Does Dogwood Therapeutics Inc stock benefit from AI growthJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Shorts Report: Is Dogwood Therapeutics Inc stock showing strong momentumDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Update: Does Dogwood Therapeutics Inc stock benefit from AI growthWeekly Stock Summary & Reliable Breakout Forecasts - baoquankhu1.vn
DWTXDogwood Therapeutics Latest Stock News & Market Updates - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Earns Buy Rating from HC Wainwright - Defense World
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Praxis Precision Medicines (PRAX) and Dogwood Therapeutics (DWTX) - The Globe and Mail
1.36%
1.40%
大文字化:
|
ボリューム (24 時間):